E
DarioHealth Corp. DRIO
$8.00 $0.506.67% NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

Company Overview

DarioHealth Corp. is a digital health and digital therapeutics company that develops and commercializes technology-enabled solutions for the management of chronic conditions. The company operates at the intersection of healthcare technology, remote patient monitoring, and value-based care, focusing on improving clinical outcomes while reducing overall healthcare costs. Its platform is designed to support both individual users and enterprise healthcare customers, including employers, health plans, and provider organizations.

The company’s primary revenue drivers are subscription-based and contract-based arrangements tied to its integrated digital health platform, which combines connected devices, mobile applications, and personalized behavioral health interventions. DarioHealth is positioned as a multi-condition digital therapeutics provider, with a strategic emphasis on addressing cardiometabolic conditions and behavioral health through a single, unified platform. Founded in 2011 and originally focused on digital diabetes management, the company has evolved through internal development and acquisitions to broaden its clinical scope and enterprise reach.

Business Operations

DarioHealth generates revenue primarily through its digital therapeutics and remote patient monitoring solutions, sold to employers, health plans, and healthcare providers, as well as through limited direct-to-consumer channels. Its core business units include DarioEngage, an employer-focused health platform, and DarioConnect, which supports provider-led chronic care management and remote monitoring programs. These offerings integrate connected medical devices, data analytics, and human coaching to deliver personalized care.

Operations span both domestic and international markets, with the majority of revenue derived from the United States. The company controls proprietary software platforms, cloud-based analytics, and FDA-cleared connected devices. A significant component of its current operating structure stems from the acquisition of Twill, Inc., which expanded DarioHealth’s behavioral health and mental wellness capabilities and added enterprise customers and partnerships within the healthcare ecosystem.

Strategic Position & Investments

DarioHealth’s strategy centers on becoming a comprehensive, multi-condition digital health platform aligned with value-based care models. Growth initiatives emphasize cross-selling multiple condition programs to existing enterprise clients, expanding reimbursement-driven offerings such as remote patient monitoring, and deepening integration with healthcare providers and payers. The company has publicly stated its focus on increasing average revenue per user and improving long-term contract value through platform consolidation.

A key strategic investment was the acquisition of Twill, Inc., which strengthened DarioHealth’s position in digital behavioral health and employer-sponsored mental health solutions. The company continues to invest in data science, artificial intelligence–driven personalization, and regulatory-cleared medical technologies to support emerging care models. While DarioHealth has indicated interest in adjacent digital health capabilities, data on future acquisitions or investments beyond publicly disclosed transactions is inconclusive based on available public sources.

Geographic Footprint

DarioHealth is headquartered in New York, United States, and maintains a significant operational presence in Israel, where much of its technology development and research activities are based. The company’s primary commercial market is North America, particularly the U.S. employer and healthcare system market, which accounts for the majority of contracted revenues.

Internationally, DarioHealth has historically marketed solutions in parts of Europe and other regions, though recent disclosures indicate a strategic concentration on the U.S. market. Its global footprint supports software development, clinical research, and enterprise sales, with international operations primarily serving as technology and innovation hubs rather than large-scale revenue centers.

Leadership & Governance

DarioHealth was founded by Erez Raphael, who has played a central role in shaping the company’s product vision and strategic direction. Leadership emphasizes clinically validated solutions, data-driven personalization, and alignment with healthcare reimbursement structures. The governance framework reflects a focus on scaling enterprise healthcare relationships while maintaining regulatory compliance in digital therapeutics.

Key executives include:

  • Erez RaphaelChief Executive Officer
  • Zvi SidiChief Financial Officer

Public disclosures identify additional senior leadership roles across technology, clinical operations, and commercial functions; however, specific titles and incumbents beyond those listed above are inconsistent across available public sources.

Data complied by narrative technology. May contain errors

Top Tech Stocks
See All »
B
NVDA NASDAQ $175.02
B
AAPL NASDAQ $253.54
B
MSFT NASDAQ $373.08
Top Consumer Staple Stocks
See All »
B
WMT NASDAQ $122.95
B
Top Financial Stocks
See All »
B
B
JPM NYSE $292.99
B
V NYSE $304.30
Top Energy Stocks
See All »
B
ENB.TO TSX $73.47
B
ENB NYSE $54.75
Top Health Care Stocks
See All »
B
LLY NYSE $902.93
B
JNJ NYSE $234.65
B
AMGN NASDAQ $350.70
Top Real Estate Stocks
See All »
B
PLD NYSE $131.30